Michele S. Milella
Advanced in Chromosome 9p Deletion

Michele S. Milella

Verona, IT 
Advanced in Chromosome 9p Deletion
Verona, IT 
OverviewLocationsClinical Research

Overview

Michele Milella practices in Verona, Italy. Milella is rated as an Advanced expert by MediFind in the treatment of Chromosome 9p Deletion. Their top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma (RCC), Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 401 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Chromosome 9p Deletion.

Locations

Verona, Italy
Other Locations
Rome, Italy
Bari, Italy
Via Elio Chianesi 53, Via, 00144, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: February 03, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

399 Total Publications

Popularity of heated-tobacco products and e-cigarettes among medical school students in Rome, Italy: factors associated with use and attitudes towards quitting.
Popularity of heated-tobacco products and e-cigarettes among medical school students in Rome, Italy: factors associated with use and attitudes towards quitting.
Journal: La Clinica terapeutica
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Milella's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 48 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile